Tavapadon

AbbVie acquires Cerevel Therapeutics for $8.7 billion, gaining CNS drugs including emraclidine for schizophrenia. This follows a $10.1 billion deal for ImmunoGen, aiming to offset Humira's patent loss. Cerevel's pipeline, with potential multibillion-dollar sales, includes treatments for epilepsy, Parkinson's, and Alzheimer’s-related psychosis.

In 2024, NeurologyLive® highlighted key neurology advancements, including FDA approvals for Parkinson's treatments, phase trial results for movement disorders, and promising gene therapy for Hunter syndrome, reflecting the field's evolving challenges and innovations.

In 2024, NeurologyLive® highlighted key neurology advancements, including FDA approvals for Parkinson's treatments, phase 3 trial successes, and promising gene therapy results for Hunter syndrome, reflecting the field's dynamic progress.

GlobalData analyzes drug development, focusing on Emraclidine, a drug for schizophrenia and Alzheimer’s psychosis, developed by Cerevel Therapeutics, a biopharmaceutical company targeting neuroscience diseases with a diverse pipeline.

AbbVie, Novo Nordisk, and Vertex Pharmaceuticals are identified as stocks potentially benefiting from a Santa Claus rally. AbbVie offers long-term growth despite a recent drug trial setback. Novo Nordisk, despite recent struggles, has strong financials and a promising pipeline. Vertex Pharmaceuticals, despite a recent stock plunge, has potential FDA approvals that could drive a rebound.

UCB is discontinuing minzasolmin development for Parkinson’s disease after the ORCHESTRA study failed to meet endpoints. The company will focus on glovadalen (UCB0022) for symptom treatment. Stock prices briefly dropped but later recovered.

AbbVie announced positive Phase III TEMPO-2 trial results for tavapadon, a D1/D5 partial agonist for early Parkinson’s disease, showing significant improvements in MDS-UPDRS scores and safety. KOLs praise its versatility and potential for dyskinesia, but market competition from existing dopamine agonists poses a challenge. Tavapadon’s success may hinge on its safety profile and differentiation in a crowded market, with expected market entry in 2028.